Monoclonal Antibodies, Biosimilars
Total Trials
11
As Lead Sponsor
2
As Collaborator
9
Total Enrollment
4,078
NCT03869034
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Phase: Phase 2
Role: Collaborator
Start: Mar 25, 2019
Completion: Dec 31, 2025
NCT04371796
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Start: May 10, 2020
Completion: Dec 30, 2021
NCT05385809
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
Phase: N/A
Start: Jun 1, 2022
Completion: Dec 31, 2023
NCT06139835
Testing if Tartarase Can Remove Dental Tartar
Role: Lead Sponsor
Start: Jun 8, 2022
Completion: Jul 6, 2022
NCT05572463
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Phase: Phase 1/2
Start: Nov 1, 2022
Completion: Dec 31, 2027
NCT05843292
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
Phase: Phase 4
Start: Jul 1, 2023
Completion: Dec 31, 2034
NCT06096909
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Start: Nov 1, 2023
Completion: Nov 1, 2027
NCT06292689
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Start: Mar 22, 2024
Completion: Mar 22, 2027
NCT06465420
A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine
Phase: Phase 1
Start: May 29, 2024
Completion: Sep 15, 2025
NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Start: Apr 30, 2025
Completion: Mar 30, 2028
NCT07061535
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Start: Aug 1, 2025
Completion: Aug 1, 2027
Loading map...